Elshad Hasanov, MD, PhD @HasanovLab

Congratulations, @ZuhairMajeed! This recognition is very well deserved and reflects your hard work, curiosity, and dedication to improving outcomes for patients with #kidneycancer. #WorldKidneyCancerDay It has been a pleasure to work with you and watch your growth as a physician-scientist. I am grateful to our entire #CodeToClinic team @HasanovLab @OSUCCC_James @Pelotonia @OhioStatePIIO @OhioStateMedOnc @OSUWexMed for their collaborative spirit and commitment to impactful research. Looking forward to seeing all that you accomplish through the @IKCCorg Cecile & Ken Youner Scholars Program and beyond. @IMG_Oncologists

Zuhair Majeed, MD @ZuhairMajeed

a week ago

So honored to receive the 2026 Cecile & Ken Youner IKCC Scholarship! 🌎🔬Following in the footprints of my mentor, Dr. Elshad Hasanov, makes this milestone especially meaningful. Incredibly grateful to him, our team at @HasanovLab and @IKCCorg for this opportunity. 🧬

3 2 19 3K 1

Proud to see our PhD student, @MostafaIHA, present his work on the single-cell and spatial landscape of RCC brain metastases @OSUCCC_James @OhioStatePIIO @Pelotonia. Using single-nucleus RNA-seq, spatial transcriptomics, and computational biology, his research explores mechanisms of immune dysfunction and therapeutic resistance in CNS metastases. Excited to see this work advance our understanding of brain metastasis biology and precision oncology. #KidneyCancer #BrainMetastases #SingleCell #SpatialTranscriptomics #PrecisionOncology #HasanovLab #OSUCCC #CodeToClinic

keyboard_arrow_left Previous keyboard_arrow_right Next

Machine learning-based transcriptomic signatures predict treatment outcomes across targeted therapy and immunotherapy regimens in renal cell carcinoma key findings: 🔹RNA-based signatures outperformed IMDC risk groups for PFS and OS stratification 🔹Treatment-specific transcriptomic models predicted binary outcome disease control vs progression 🔹Molecular signatures provided prognostic information beyond standard clinical risk models 🔹Supports development of precision oncology tools to personalize RCC treatment selection 📜asco.org/abstracts-pres… 📽️hasanov-lab.github.io/gallery/

Excited to share our #ASCO26 presentation from the @OhioStatePIIO @HasanovLab Biomedical Informatics PhD Student #PengLi and collaborators! Machine learning-based transcriptomic signatures predict treatment outcomes across targeted therapy and immunotherapy regimens in renal cell carcinoma 📽️hasanov-lab.github.io/gallery/ 📜asco.org/abstracts-pres… Congratulations to #PengLi and the entire @OhioStateMed @OSUCCC_James #Buckeye team: @OSUWexMed @OhioStateMedOnc @OSU_Urology #OSUPathology @eric_facs @FuatBicer #AmirMortazavi @KimrynRathmell @ZuhairMajeed @semihaxozgul #KidneyCancer #RenalCellCarcinoma #AIinMedicine #MachineLearning #PrecisionOncology #CancerResearch #ASCO #Oncology #TranslationalResearch #CodeToClinic @OSUCCC_James @ASCO @ASCOTECAG @KidneyCancer @OncoAlert @oncodaily @OncLive @urotoday

Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases @BetulGokYavuz1 @ASCO #ASCO26 Key findings: 🧠RCC brain metastases harbor distinct copy-number alterations (CNAs) compared with primary tumors. 🧬Recurrent alterations involving 8p loss, 8q gain, and 9p21.3 deletionwere enriched in brain metastases across all cancers. 📈These CNA patterns were associated with worse survival and may contribute to brain metastatic progression. 🤖Using genomic features, we developed a machine learning model that identified patients at increased risk of mortality/brain metastasis.

Excited to share our #ASCO2026 poster presentation by our postdoc alumni @BetulGokYavuz1 @UChicago 🌟 physician👩‍⚕️👩‍🔬scientist Heme/Onc fellow. Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases 📜biorxiv.org/content/10.648… 📽️ hasanov-lab.github.io/gallery/ This study could not have been possible without multi-institutional collaboration and support from @UTMDAnderson @EJonasch @WinshipAtEmory @bilenma @Hacettepe1967 @hanalioglu @HKUniversity #DavidJHShih, funding and resources @kidneycancer, @OSUCCC_James @OhioState @OSUPIIO, @HasanovLab bioinformatics team #PengLi @joseovandor @AleLaFerlita90 #KidneyCancer #RCC #BrainMetastases #PrecisionOncology #CancerGenomics #MachineLearning @ASCOTECAG @OSUCCC_James @ASCOPost @ASCO @kidneycancer @kidneycan @urotoday @OncoAlert @oncodaily @OncLive

Key findings of @ShriyaDeshmukh3 presentation at #ASCO26, the spatial transcriptomic profiling of the tumor microenvironment in metastatic RCC treated with sunitinib: 🔹Sunitinib resistance is associated with a profoundly immunosuppressive TME 🔹Enrichment of myeloid suppressive programs (SPP1+ macrophages)and T-cell exhaustion 🔹Increased angiogenesis, extracellular matrix remodeling, and hypoxia-related pathways 🔹Adaptive metabolic reprogramming emerges in resistant tumors 🔹Machine learning-derived spatial signatures predicted survival in an independent external cohort

Congratulations to our star Heme/Onc fellow, @ConquerCancerFd #ASCOMeritAwardee @ShriyaDeshmukh3, presenting at #ASCO26, the spatial transcriptomic profiling of the tumor microenvironment in metastatic RCC treated with sunitinib. If you missed the presentation: hasanov-lab.github.io/gallery/ We are grateful to our collaborators at @UTMDAnderson, @EJonasch, for leading this IIT and @KidneyCancer, @sitcancer, @OhioStatePIIO for funding correlative studies, @HasanovLab bioinformaticians @MostafaIHA @joseovandor leading analysis. #ASCO26 #SpatialTranscriptomics #TumorMicroenvironment #PrecisionOncology #MachineLearning #CodeToClinic @ASCOTECAG @OhioState @OhioStateMedOnc @OSUCCC_James @ASCO @Pelotonia

@tompowles1 @Uromigos @DrChoueiri Impressive to see the absolute risk reduction with pembrolizumab at 24 months in ctDNA+ group is 20%, vs in ctDNA- group is 7%. A new chapter for RCC adjuvant care with hopefully more sensitive tests soon. Congrats @DrChoueiri and team for this great study!

@IamLinghua @ScienceMagazine Congratulations Linghua excellent work!

🚨🚨Multiple Brain Mets Randomized Trial🚨 · Significantly less symptom burden with SRS compared to HA-WBRT · Better ADL, cognition & KPS after SRS · SRS Standard of Care 5-20 brain mets jamanetwork.com/journals/jama/…

@DrKarineTawagi @arkhaki @PriyankaChabla1 @PGrivasMDPhD @oncologydoc @shilpaonc @ERPlimackMD @DrRosenbergMSK @koshkin85 @urotoday @oncodaily @BladderCancerUS @IBCG_BladderCA @WorldBladderCan The only available data so far would support the ICI rechallege after >1y of previous ICI @ESMO_Open @BrigidaMaiorano sciencedirect.com/science/articl…

Can we stop excluding brain Mets from clinical trials. These patients need therapy. DART showed that brain Mets did not compromise safety or activity. pubmed.ncbi.nlm.nih.gov/41378983/

This interdisciplinary consensus effort sought to standardize practical management strategies of single & multiple brain mets in patients with #RenalCellCarcinoma. Authors present a framework to guide treatment decisions for patients. #AUC3 acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @OncoAlert

Mapping heterogeneity in the tumor microenvironment of #RenalCellCarcinoma through single-cell omics. #AuthorCommentary on UroToday, Single-cell and spatial technologies are uncovering profound heterogeneity in the #RCC tumor microenvironment—reshaping how we understand CD8⁺ T-cell exhaustion, myeloid diversity, and cancer-associated fibroblasts. These high-resolution insights are paving the way for better biomarkers and more precise, personalized immunotherapy in RCC. #ReadNow > bit.ly/4qYzI0Q @CellPressNews #TrendsinCancer @BetulGokYavuz1 @nkhanmam @ZuhairMajeed @mostafa96721868 @bilenma @eric_facs @HasanovLab

As 2025 comes to a close, @David_Cohn_MD, @DrRPollock and I thought we’d take a moment to celebrate stories this year that show why @OSUCCC_James is such a powerhouse against cancer. Here is a thread of 25 inspiring cancer stories in '25: 🧵

Happening now! The 7th Annual #PIIO Symposium Poster Session at Marriott OSU (3100 Olentangy River Rd, Cbus, OH). 🚀 Much more to come with the reception & Director's Address by Dr. @Zihai Li! @OSUCCC_James @Pelotonia #Immuno_Oncology

keyboard_arrow_left Previous keyboard_arrow_right Next

A perfect holiday-season read with hot chocolate & cookies ☕️🍪❄️ @trendscancer “Mapping Heterogeneity in the Tumor Microenvironment of Renal Cell Carcinoma Through Single-Cell Omics” Led by our rising star physician-scientist @BetulGokYavuz1 ✨ Free link: authors.elsevier.com/a/1mCdH8Z12ybX… Grateful for the @trendscancer editorial support, excellent reviewers, and our passionate team & collaborators @OhioStatePIIO @OSUCCC_James @OSUWexMed @kidneycancer @kidneycan @IKCCorg 🙌

keyboard_arrow_left Previous keyboard_arrow_right Next